In conclusion, this study suggests that p53 overexpression phenotype (≥50%) can identify a subgroup of patients with a more favorable prognosis, and this finding could potentially push the boundaries of genomic medicine for patients with EGFR-mutated lung adenocarcinoma with TP53 co-mutations. This evidence concerns the gene TP53 and lung adenocarcinoma.